LONDON--(BUSINESS WIRE)--Technavio has announced their latest analysis report on drug pipeline for hyperoxaluria. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat hyperoxaluria.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Hyperoxaluria: Market overview
Hyperoxaluria is a state of disordered metabolism characterized by an increased urinary excretion of oxalate. The daily oxalate excretion in healthy individuals ranges between 10 mg and 40 mg per 24 hours. Concentrations exceeding 40-45 mg per 24 hours are considered as clinical hyperoxaluria. Hyperoxaluria is of several types including primary hyperoxaluria, oxalosis, enteric hyperoxaluria, hyperoxaluria related to eating high-oxalate foods.
According to a senior market research analyst at Technavio, “The worldwide prevalence of primary hyperoxaluria is estimated to affect one in 58,000 individuals. One estimate places the prevalence of primary hyperoxaluria type I at 1-3 cases per 1,000,000 people in the general population, and the incidence at one case per 120,000 live births per year in Europe. Hyperoxaluria is uncommon, though it can be found in about 20% of individuals with kidney stones.”
Hyperoxaluria: Segmentation analysis
This pipeline analysis report segments the hyperoxaluria market based on therapies employed (monotherapy), RoA (oral and subcutaneous), therapeutic modality (enzyme, SiRNA, and biological), targets (oxalate, glycolate oxidase, LDHA gene, and hydroxyacid oxidase 1), MoA (oxalate degraders, reduces hepatic glycolate oxidase, silences the LDHA gene, and gene transfer), geographical segmentation (US, UK, Spain, Netherlands, Germany, France, Jordan, Israel and Belgium) and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 50% of the molecules that are being investigated for the treatment of hyperoxaluria are enzymes.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.